Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? Michelle A

Total Page:16

File Type:pdf, Size:1020Kb

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? Michelle A Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ? Michelle A. Crisher,1 Christopher A. Giuliano,1,2 and Carrie L. Hartner1 FEATURE ARTICLE FEATURE ■ IN BRIEF Several studies have compared the safety and efficacy of insulin detemir and insulin glargine; however, most have been conducted in the ambulatory care setting. This retrospective cohort study compared hypoglycemia rates between the two basal insulin analogs in hospitalized patients with diabetes. No difference was found between the two insulin cohorts in the proportion of patients who experienced hypoglycemic events. n 2015, it was estimated that ~30.3 Detemir is also derived using recom- million Americans were living binant technology and, when injected, Iwith type 1 or type 2 diabetes (1). forms a soluble depot. In addi- Common long-term complications tion, acylation and self-association of uncontrolled diabetes include properties of detemir allow for end-stage renal disease, diabetic reti- reversible binding to albumin, which nopathy, amputations, and increased results in its prolonged duration of hospitalizations (2,3). In the inpatient action. Detemir’s duration of action setting, hyperglycemia, hypoglycemia, on blood glucose varies from 6 to 23 and blood glucose variability can lead hours and is largely dose dependent, to increased costs, lengths of stay, and with longer duration observed as mortality (4,5). Long-acting insulin dosage increases (6,9). Glargine and analogs remain one of the mainstays detemir may be administered once of therapy in the management of or twice daily depending on medica- blood glucose in patients with diabe- tion and patient considerations (8,9). tes (5). Two commonly used basal in- These can include basal insulin dose, sulin analogs are insulin glargine and prandial insulin use, glycemic target, insulin detemir. patient preference, and endogenous Detemir and glargine exhibit insulin reserve (10–12). similar pharmacokinetic and phar- Studies comparing the safety and macodynamic profiles, which make efficacy of detemir and glargine have them appropriate for basal therapy. been done mostly in the ambulatory 1Ascension St. John Hospital, Detroit, MI Both demonstrate a peakless time- care setting and have demonstrated action profile and a long duration of similar glycemic control when added 2Wayne State University Eugene Applebaum College of Pharmacy and action, although they achieve this to mealtime insulin or oral medica- Health Sciences, Detroit, MI through different absorption mecha- tions in patients with type 2 diabetes Corresponding author: Christopher A. nisms (6,7). Glargine is derived using (13,14). In contrast, a subgroup of Giuliano, [email protected] recombinant technology and forms the PREDICTIVE study (15) found https://doi.org/10.2337/cd18-0065 a precipitate that dissolves slowly at improvements in glycemic control physiologic pH, thus delaying absorp- and a reduction of hypoglycemic ©2018 by the American Diabetes Association. Readers may use this article as long as the work tion. This delayed absorption allows events when switching patients is properly cited, the use is educational and not for a duration of action that ranges with type 1 or type 2 diabetes from for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0 from 10 to 24 hours, reaching up glargine to detemir at routinely for details. to ~30 hours in a few studies (6,8). scheduled clinic visits (15). CLINICAL DIABETES 1 Clinical Diabetes Online Ahead of Print, published online October 17, 2018 FEATURE ARTICLE Despite the breadth of compar- cause a transition of preferred formu- Outcomes ative literature surrounding basal lary agent (from glargine to detemir) The primary outcome was the pro- insulin therapy in the ambulatory occurred during this time. Patients portion of patients who experienced care environment, there is a paucity were identified via active orders for hypoglycemia within 72 hours of evidence comparing the safety either detemir or glargine within the of initiating detemir or glargine. and efficacy of glargine and detemir electronic medical record (EMR) sys- Hypoglycemia was defined as a blood in hospitalized patients. Galindo et tem. EMRs of adult patients with a glucose value <70 mg/dL. Secondary al. (16) performed a retrospective diagnosis of diabetes and an order outcomes included the proportion database analysis of glargine and for detemir or glargine were reviewed of patients who experienced hyper- detemir use in hospitalized patients for inclusion. Patients were excluded glycemic events, the total number of who had either type 1 or type 2 dia- if they were pregnant, had received hypoglycemic events, and total in- betes. No difference in average blood a continuous insulin infusion, had sulin requirements within 72 hours glucose values was noted between the received detemir or glargine for <72 of detemir or glargine initiation. two insulin cohorts throughout the hours, were admitted to an intensive Hyperglycemia was defined as a blood > hospital stay. Similarly, there were care unit (ICU), or had missing data glucose value 180 mg/dL. no differences in maximum blood needed for analysis (missing both Data Analysis glucose or number of patients with height and weight, having no blood Our sample size was based on an severe hyperglycemia. Interestingly, glucose measurements, or missing se- overall rate of hypoglycemia in the there was an increase in hypoglyce- rum creatinine [SCr] values) within detemir group of 33.5% compared to mic events in the detemir cohort. 29% for the glargine group, with an Patients who received detemir also 72 hours of initiation of either de- alpha error rate of 0.05 and 80% pow- received higher total daily doses temir or glargine. Institutional review er (16). To find this difference, a sam- (TDDs) of insulin, as well as more board approval was obtained before ple size of 1,659 patients per group daily injections. In contrast, Zhang the study commenced. was needed, for a total of 3,318 pa- et al. (17) performed a prospective Data Collection tients. Data were analyzed using SPSS randomized crossover trial comparing Data were electronically abstract- version 25.0 software (IBM Corp., glargine and detemir in hospital- ed from the EMR system using Armonk, N.Y.). Descriptive data were ized patients with type 2 diabetes. Access 2016 software (Microsoft expressed as mean ± SD, median ± The authors concluded that the two Corp., Redmond, Wash.) to ex- interquartile range, or frequency and insulins demonstrated similar time tract International Classification of percentage. Univariate analysis was to fasting blood glucose target and Diseases 9th or 10th revision codes performed using a Student t test, a similar TDDs. Hypoglycemic events and Excel 2016 software (Microsoft Mann Whitney U test, or a χ2 test for occurred in three of the patients Corp, Redmond, Wash.) to extract continuous, ordinal, and categorical switched to detemir. However, this all other data. Authors M.A.C. and data, respectively. Multivariate logistic analysis was limited to 42 patients, C.A.G. organized the extracted data. regression was performed using hypo- thus restricting its power to detect Data collected within 72 hours of de- glycemia as the dependent variable. safety events of statistical significance. temir or glargine initiation included Variables were initially considered for More evidence comparing glargine highest and lowest creatinine clear- inclusion into the model if there was and detemir in the inpatient environ- a difference between the detemir and ment is necessary. The purpose of this ance, all blood glucose values, short- glargine groups and there was an asso- study was to compare the efficacy and acting insulin, sliding scale type, insu- ciation with hypoglycemia (P < 0.1). safety profiles of glargine and detemir lin TDD, nothing-by-mouth status, by exploring the incidence of both acute kidney injury, chronic kidney Results hypoglycemia and hyperglycemia in disease, corticosteroids, beta-blockers, Of the 5,200 patients initially hospitalized patients with diabetes. total parenteral nutrition, enteral screened, 3,726 were identified for nutrition, and specific infections, Design and Methods inclusion. A total of 3,318 patients including urinary tract infection, (1,659 in each cohort) were randomly Sample Selection pneumonia, bacteremia, and diabetic selected for the final data analysis. The This retrospective cohort study was foot infection. Data collected outside most common reason for exclusion conducted at a 772-bed community of 72 hours included baseline demo- was no diagnosis of diabetes. Figure teaching hospital in patients with a graphics, length of stay, long-acting 1 shows an inclusion and exclusion diagnosis of type 1 or type 2 diabetes insulin taken before admission, and flowchart. Baseline characteristics between January 2010 to November most recent A1C. Electronically ab- are summarized in Table 1 and were 2017. Data from the month of stracted data were manually validated mostly similar between the two co- December 2013 were not collected be- by examining 50 patients per cohort. horts. The detemir cohort included 2 CLINICAL.DIABETESJOURNALS.ORG Clinical Diabetes Online Ahead of Print, published online October 17, 2018 CRISHER ET AL . confounders, multivariate regression analysis was performed (Table 2). Age, baseline SCr, high-intensity insulin scale, and concomitant cor- ticosteroid use all met criteria to be included in the final model. When controlling
Recommended publications
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Combining a Glucagon-Like Peptide-1 Receptor Agonist with Basal Insulin: the Why and How
    Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. A year-and-a- half ago, basal insulin was added to her lifestyle and metformin management. She now administers 52 units (0.62 units/kg) once daily at bedtime. Since starting basal insulin, she has experienced 3 episodes of mild hypoglycemia. Since her diagnosis, Mary’s HbA1c has never been <7.0%; her current HbA1c is 7.9%. Over the past month, her fasting plasma glucose (FPG) has ranged from 103 mg/dL to 136 mg/dL and her postprandial glucose (PPG) from 164 mg/dL to 213 mg/dL. She has gained 2.6 kg since starting basal insulin and her body mass index is now 31 kg/m2. Her blood pressure is 134/82 mmHg. She experiences occasional tingling in her feet. Eye examination reveals grade 1 retinopathy. Current medications are: metformin 1000mg twice daily, basal insulin 52 units once daily at bedtime, and hydrochlorothiazide 25 mg once daily. Her family physician notes that Mary’s FPG is reasonably well-controlled, yet her HbA1c and PPG remain elevated. He is also concerned about her episodes of hypoglycemia and weight gain and the evidence indicating microvascular damage.
    [Show full text]
  • A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D
    Drugs 2005; 65 (3): 325-340 REVIEW ARTICLE 0012-6667/05/0003-0325/$39.95/0 2005 Adis Data Information BV. All rights reserved. A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D. Mooradian Division of Endocrinology, Department of Internal Medicine, Diabetes, and Metabolism, St Louis University School of Medicine, St Louis, Missouri, USA Contents Abstract ....................................................................................325 1. Physiology of Insulin Secretion .............................................................326 2. Conventional Insulin Preparations ..........................................................327 3. Insulin Analogues ........................................................................328 3.1 Rapid-Acting Insulin Analogues .......................................................328 3.1.1 Insulin Lispro ...................................................................328 3.1.2 Insulin Aspart ..................................................................329 3.1.3 Insulin Glulisine .................................................................329 3.1.4 Clinical Utility of Rapid-Acting Insulin Analogues ...................................330 3.2 Premixed Insulins and Insulin Analogues ................................................331 3.3 Basal Insulin Analogues ...............................................................331 3.3.1 Insulin Glargine ................................................................331
    [Show full text]
  • Effects of Exenatide on Cardiac Function, Perfusion, and Energetics
    Chen et al. Cardiovasc Diabetol (2017) 16:67 DOI 10.1186/s12933-017-0549-z Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine Weena J. Y. Chen1*, Michaela Diamant1^, Karin de Boer2, Hendrik J. Harms3, Lourens F. H. J. Robbers2, Albert C. van Rossum2, Mark H. H. Kramer1, Adriaan A. Lammertsma3 and Paul Knaapen2 Abstract Background: Multiple bloodglucose-lowering agents have been linked to cardiovascular events. Preliminary studies showed improvement in left ventricular (LV) function during glucagon-like peptide-1 receptor agonist administration. Underlying mechanisms, however, are unclear. The purpose of this study was to investigate myocardial perfusion and oxidative metabolism in type 2 diabetic (T2DM) patients with LV systolic dysfunction as compared to healthy controls. Furthermore, efects of 26-weeks of exenatide versus insulin glargine administration on cardiac function, perfusion and oxidative metabolism in T2DM patients with LV dysfunction were explored. Methods and results: Twenty-six T2DM patients with LV systolic dysfunction (cardiac magnetic resonance (CMR) derived LV ejection fraction (LVEF) of 47 13%) and 10 controls (LVEF of 59 4%, P < 0.01 as compared to patients) were analyzed. Both myocardial perfusion± during adenosine-induced hyperemia± (P < 0.01), and coronary fow reserve 15 (P < 0.01), measured by ­[ O]H2O positron emission tomography (PET), were impaired in T2DM patients as compared to healthy controls. Myocardial oxygen consumption and myocardial efciency, measured using ­[11C]acetate PET and CMR derived stroke volume, were not diferent between the groups.
    [Show full text]
  • OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ These highlights do not include all the information needed to use Personal or family history of medullary thyroid carcinoma or in patients OZEMPIC® safely and effectively. See full prescribing information with Multiple Endocrine Neoplasia syndrome type 2 (4). for OZEMPIC. Known hypersensitivity to OZEMPIC or any of the product components (4). OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Pancreatitis: Has been reported in clinical trials. Discontinue promptly if WARNING: RISK OF THYROID C-CELL TUMORS pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). See full prescribing information for complete boxed warning. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). In rodents, semaglutide causes thyroid C-cell tumors. It is Never share an OZEMPIC pen between patients, even if the needle is unknown whether OZEMPIC causes thyroid C-cell tumors, changed (5.4). including medullary thyroid carcinoma (MTC), in humans as Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or the human relevance of semaglutide-induced rodent thyroid C- insulin, consider lowering the dose of the secretagogue or insulin to reduce cell tumors has not been determined (5.1, 13.1). the risk of hypoglycemia (5.5). OZEMPIC is contraindicated in patients with a personal or Acute Kidney Injury: Monitor renal function in patients with renal family history of MTC or in patients with Multiple Endocrine impairment reporting severe adverse gastrointestinal reactions (5.6). Neoplasia syndrome type 2 (MEN 2).
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes – Systematic Review of the Evidence Evidence-Based Synthesis Program APPENDIX E
    Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes – Systematic Review of the Evidence Evidence-based Synthesis Program APPENDIX E. EVIDENCE TABLES Table 1. Characteristics of Included Studies Author Study Design Intervention/ Date Data Sources Control Definition of Severe Inclusion/Exclusion Criteria Patient Characteristics Study Quality Country Length of Hypoglycemia Funding Source Follow-up Target HbA1c Abraira 199530 RCT Inclusion criteria: N=153 Intensive group: Impaired consciousness Allocation Men ages 40-69, with non-insulin Age: 60.2 years stepped regimen of requiring the help Concealment: Yes United States 27 months dependent diabetes who were being % male: 100 insulin goal of HbA1c of another person, (VA Cooperative treated with insulin or judged clinically to Race/ethnicity: =5.1+/-1% or coma, or seizure; Blinding: Yes Study) require insulin because of failure of other White=49.5 confirmed low blood therapy Black=24 Standard group: one or glucose concentration Intention-to-Treat Government Exclusion criteria: Other=3 two injections of insulin/ or rapid response to Analysis (ITT): No Serious illness or predicted poor BMI: 31.0 day treatments expected to compliance, diagnosed >15 years prior Duration of diabetes: 7.8 years Goal was to avoid raise the level of blood Withdrawals/dropouts History of MI: 13.7% diabetic symptoms, glucose also required adequately described: History of CHF: 2.0% excessive glycosuria, or Yes History of CVA: 6.5% overt hypoglycemia Current smoker: 15% ACCORD 2008;3 RCT Inclusion
    [Show full text]
  • Insulin Glargine (HOE901) First Responsibilities: Understanding the Data and Ensuring Safety
    EDITORIAL Insulin Glargine (HOE901) First responsibilities: understanding the data and ensuring safety n this issue, Heinemann et al. (1) and Rat- decline in activity through the duration of other journals. They leave the reader with ner et al. (2) provide the results of stud- the 30-h study. The authors conclude that a sense of promise, but without the firm Iies of insulin glargine (formerly known as insulin glargine provides a flatter metabolic conviction that insulin glargine is clearly HOE901), the most recent addition to the profile than NPH insulin. Theoretically, this superior to other long-acting forms of growing family of insulin analogs and for- could prove to be advantageous in accom- insulin. The pharmacodynamic study sug- mulations. The authors report insulin modating the basal insulin requirements of gests that the peakless profile of action glargine’s pharmacodynamic characteristics patients with diabetes. should provide an advantage that can be (1) and data concerning its safety and effi- Ratner et al. (2) report initial results for used to produce clinically meaningful cacy when administered to subjects with the U.S. Study Group of Insulin Glargine in improvements in glycemic control. The type 1 diabetes who were treated with reg- Type 1 Diabetes. In their article, they clinical trial’s demonstration of a reduction ular insulin (2). Insulin glargine is produced describe the results of a large randomized in hypoglycemia and in fasting plasma glu- by recombinant DNA technology with 2 prospective 28-week trial of insulin cose levels appears to provide an opportu- modifications of the native human insulin glargine versus NPH insulin.
    [Show full text]
  • Complaint for Declaratory 19 and Injunctive Relief Biotechnology Innovation 20 Organization
    Case 2:17-cv-02315 Document 1 Filed 09/01/17 Page 1 of 44 1 Pat Lundvall Nevada Bar No. 3761 2 MCDONALD CARANO LLP 2300 West Sahara Avenue, Suite 1200 3 Las Vegas, NV 89102 Telephone: (702) 873-4100 4 [email protected] 5 Robert N. Weiner Pending Admission Pro Hac Vice 6 Jeffrey L. Handwerker Pending Admission Pro Hac Vice 7 R. Stanton Jones Pending Admission Pro Hac Vice 8 ARNOLD & PORTER KAYE SCHOLER LLP 601 Massachusetts Avenue, NW 9 Washington, DC 20001 Telephone: (202) 942-5000 10 [email protected] [email protected] 11 [email protected] 12 Attorneys for Plaintiffs Pharmaceutical 13 Research and Manufacturers of America and Biotechnology Innovation Organization 14 15 UNITED STATES DISTRICT COURT 16 DISTRICT OF NEVADA 17 PHARMACEUTICAL RESEARCH AND Case No.: 18 MANUFACTURERS OF AMERICA, and COMPLAINT FOR DECLARATORY 19 AND INJUNCTIVE RELIEF BIOTECHNOLOGY INNOVATION 20 ORGANIZATION, 21 Plaintiffs, 22 vs. 23 BRIAN SANDOVAL, in his official capacity 24 as Governor of the State of Nevada, and 25 RICHARD WHITLEY, in his official capacity as Director of the Nevada Department for 26 Health and Human Services, 27 Defendants. 28 Case 2:17-cv-02315 Document 1 Filed 09/01/17 Page 2 of 44 1 Plaintiffs Pharmaceutical Research and Manufacturers of America (“PhRMA”) and 2 Biotechnology Innovation Organization (“BIO”) (together, “Plaintiffs”), on behalf of themselves 3 and their members, for their Complaint against Brian Sandoval, in his official capacity as Governor 4 of the State of Nevada (the “State”), and Richard Whitley, in his official capacity as Director of the 5 Nevada Department of Health and Human Services (together, “Defendants”), allege as follows: 6 INTRODUCTION 7 1.
    [Show full text]
  • Study Protocol
    CLINICAL TRIAL REPORT ZP4207-17086 (ZEA-DNK-02170) 16.1 TRIAL INFORMATION 16.1.1 PROTOCOL AND PROTOCOL AMENDMENTS This appendix includes Document Date, Version Clinical trial protocol Version 1.0, 08 June 2018 (valid in Slovenia and the USA) Version 3.0, 08 January 2019 (valid in Germany) Section 16.1.1: Protocol and Protocol Amendments Clinical Trial Protocol, final version 1.0 ZP4207-17086 (ZEA-DNK-02170) Clinical Trial Protocol A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when administered as a rescue therapy for severe hypoglycemia in children with T1DM treated with insulin Sponsor code: ZP4207-17086 Synteract: ZEA-DNK-02170 EudraCT number: 2018-000892-33 Coordinating investigator: Prof. Dr. med. Thomas Danne Allgemeine Kinderheilkunde Diabetologie, Endokrinologie, Klinische Forschung Diabeteszentrum für Kinder und Jugendliche AUF DER BULT Kinder- und Jugendkrankenhaus Janusz-Korczak-Allee 12 30173 Hannover Germany Sponsor: Zealand Pharma A/S Smedeland 36 2600 Glostrup, Copenhagen Denmark Version: final version 1.0 Date: 08 June 2018 GCP statement This trial will be performed in compliance with Good Clinical Practice, the Declaration of Helsinki (with amendments) and local legal and regulatory requirements. 08 June 2018 CONFIDENTIAL Page 1/55 Zealand Pharma A/S ClinicalTrial Prolocol, final ve¡sion 1.0 zP 42A7 -1 7 A 86 (ZEA-DN K-02 1 L Slgnature¡ and agreoment wlth protocot Tltle: phase A 3, ¡andomized, double-blind, placebo- and aclivg-controlled, parallel-arm trial to assess the efficac¡ safety, and pharmacoítinetics of dasiglucagon rela¡ve to placebo and GlucaGeno when edministered as a rescue thêrapy for sevãre triposivcemia ¡n children w¡th TlDM treated with insulin we, the undersigned, agroe to conduct lhls trlal according to lhe Trlal protocol.
    [Show full text]
  • GLP-1 Agonists and Long-Acting Insulin Combination Therapy
    Disclosure GLP-1 Agonists and I have no conflicts of interest to disclose. Long-Acting Insulin Combination Therapy Jeanna Sewell, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy Objectives Long-Acting Insulin Lantus ® (insulin glargine) . Lower blood glucose At the end of this presentation, the audience should be (BG) throughout the able to: day Explain the mechanism of GLP-1 agonists Levemir ® (insulin detemir) . Does not target Identify advantages and disadvantages of combination GLP-1 post-prandial BG agonists and long-acting insulin combination products (PPBG) Discuss the potential role in therapy of GLP-1 agonist and long- acting insulin combination products Toujeo ® (insulin glargine U-300) . Dosed once or twice daily Tresiba ® (insulin degludec) Glucagon-like Peptide-1 Agonists (GLP-1) GLP-1 Receptor Agonists exenatide (Byetta®, Bydureon®) Benefits: Weight loss Glucose-dependent mechanism liraglutide (Victoza®) Lower A1C 1-1.5% Side effects: Nausea, HA, diarrhea albiglutide (Tanzeum®) Pancreatitis BBW: Medullary thyroid carcinoma TM Multiple endocrine neoplasia syndrome 2 dulaglutide (Trulicity ) (MEN2) Lixisenatide (Adlyxin®) Image from http://www.gastrojournal.org/article/S0016-5085(07)00580-X/fulltext?refuid=S0002-8223(09)02093-8&refissn=0002-8223 Potential Role in Therapy Soliqua (insulin glargine and lixisenatide) ADA Standards of Care 2017 Available in retail pharmacies January 2017 Safety FDA Approved Indication: patients with Type 2 diabetes who are uncontrolled
    [Show full text]
  • Insulin Glargine
    Pharmacy Benefit Coverage Criteria Effective Date ............................................ 3/1/2021 Next Review Date… ..................................... 3/1/2022 Coverage Policy Number ................................ P0023 Insulin glargine Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 Quantity Limitations FDA Summary ..................................................... 2 Background .......................................................... 2 References .......................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s
    [Show full text]